Envigo has launched a program of in vitro technologies aimed at helping to predict the likelihood of compounds causing drug induced livery injury (DILI) – one of the major causes of drugs being withdrawn from the market.   The new DILI Assessment program can help identify whether a drug exhibits possible risk factors associated with hepatotoxicity. The program can be run in full, using all of its tests, or can be conducted using single assays as required.   “Envigo’s battery of in vitro test...